KR100865410B1 - 진정 및 운동실조 효과가 감소된 항불안제 - Google Patents

진정 및 운동실조 효과가 감소된 항불안제 Download PDF

Info

Publication number
KR100865410B1
KR100865410B1 KR1020047015305A KR20047015305A KR100865410B1 KR 100865410 B1 KR100865410 B1 KR 100865410B1 KR 1020047015305 A KR1020047015305 A KR 1020047015305A KR 20047015305 A KR20047015305 A KR 20047015305A KR 100865410 B1 KR100865410 B1 KR 100865410B1
Authority
KR
South Korea
Prior art keywords
compound
mmol
mixture
phenyl
delete delete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020047015305A
Other languages
English (en)
Korean (ko)
Other versions
KR20040098029A (ko
Inventor
제임스 엠. 쿡
퀴 후앙
쟈오휘 헤
죠아얀 리
쟌밍 유
동메이 한
Original Assignee
위시스 테크놀로지 파운데이션, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 위시스 테크놀로지 파운데이션, 인크. filed Critical 위시스 테크놀로지 파운데이션, 인크.
Publication of KR20040098029A publication Critical patent/KR20040098029A/ko
Application granted granted Critical
Publication of KR100865410B1 publication Critical patent/KR100865410B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/141,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/121,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/141,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/161,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/181,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/20Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/141,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/161,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/181,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
KR1020047015305A 2002-03-28 2003-03-28 진정 및 운동실조 효과가 감소된 항불안제 Expired - Fee Related KR100865410B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36840802P 2002-03-28 2002-03-28
US60/368,408 2002-03-28
PCT/US2003/009587 WO2003082832A2 (en) 2002-03-28 2003-03-28 Anxiolytic agents with reduced sedative and ataxic effects

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020087012062A Division KR20080060286A (ko) 2002-03-28 2003-03-28 진정 및 운동실조 효과가 감소된 항불안제

Publications (2)

Publication Number Publication Date
KR20040098029A KR20040098029A (ko) 2004-11-18
KR100865410B1 true KR100865410B1 (ko) 2008-10-24

Family

ID=28675480

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020047015305A Expired - Fee Related KR100865410B1 (ko) 2002-03-28 2003-03-28 진정 및 운동실조 효과가 감소된 항불안제
KR1020087012062A Ceased KR20080060286A (ko) 2002-03-28 2003-03-28 진정 및 운동실조 효과가 감소된 항불안제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020087012062A Ceased KR20080060286A (ko) 2002-03-28 2003-03-28 진정 및 운동실조 효과가 감소된 항불안제

Country Status (16)

Country Link
US (6) US7119196B2 (https=)
EP (1) EP1490344B1 (https=)
JP (1) JP2005525392A (https=)
KR (2) KR100865410B1 (https=)
CN (1) CN1642924A (https=)
AT (1) ATE389640T1 (https=)
AU (1) AU2003230754B2 (https=)
BR (1) BR0308918A (https=)
CA (1) CA2480869A1 (https=)
DE (1) DE60319812T2 (https=)
DK (1) DK1490344T3 (https=)
ES (1) ES2300576T3 (https=)
IL (1) IL163958A0 (https=)
MX (1) MXPA04009332A (https=)
NZ (1) NZ535517A (https=)
WO (1) WO2003082832A2 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE47475E1 (en) * 2002-03-28 2019-07-02 Wisys Technology Foundation, Inc. Selective agents for pain suppression
CA2570185A1 (en) * 2004-06-30 2006-01-12 Wisys Technology Foundation Inc. Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects
US8119629B2 (en) 2007-10-03 2012-02-21 Bristol-Meyers Squibb Company Carboxamide GABAA α2 modulators
JP5345637B2 (ja) * 2008-01-22 2013-11-20 イーライ リリー アンド カンパニー κ選択的オピオイド受容体アンタゴニスト
US20100261711A1 (en) * 2009-03-20 2010-10-14 Wisys Technology Foundation Selective anticonvulsant agents and their uses
JP2013209292A (ja) * 2010-07-23 2013-10-10 Nippon Chemiphar Co Ltd P2x4受容体拮抗剤
US9006233B2 (en) 2011-04-28 2015-04-14 Uwm Research Foundation, Inc. Gabaergic receptor subtype selective ligands and their uses
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain
CA2885148A1 (en) 2012-09-21 2014-03-27 Uwm Research Foundation, Inc. Novel gabaa agonists and methods of using to control airway hyperresponsiveness and inflammation in asthma
FR3010785B1 (fr) * 2013-09-18 2015-08-21 Snecma Procede de controle de la densite d'energie d'un faisceau laser par analyse d'image et dispositif correspondant
SG11201806393QA (en) 2016-01-27 2018-08-30 Univ Zuerich Use of gabaa receptor modulators for treatment of itch
DK3439665T3 (da) 2016-03-18 2022-09-26 Uwm Res Foundation Inc Behandling af kognitive og sindsstemningssymptomer ved neurodegenerative og neuropsykiatriske lidelser med alpha5-holdige gabaa-receptoragonister
JP7013446B2 (ja) 2016-08-16 2022-02-15 ユーダブリューエム・リサーチ・ファウンデーション,インコーポレーテッド Gaba(a)受容体モジュレーター、及び、喘息における気道過敏及び炎症を抑制するための方法
JP7139323B2 (ja) * 2016-11-01 2022-09-20 エフ.ホフマン-ラ ロシュ アーゲー Cns関連疾患を処置するための1,3-ジヒドロ-1,4-ベンゾジアゼピン-2-チオン
CN107056760A (zh) * 2017-01-22 2017-08-18 苏州楚凯药业有限公司 5,7位取代的1H‑苯并[e][1,4]二氮杂‑2(3H)‑酮衍生物的制备方法
CN107216332B (zh) * 2017-06-29 2019-04-30 上海药明康德新药开发有限公司 叔丁基-7-羟甲基-7,8-二氢4h吡唑并二氮杂卓5(6h)甲酸基酯的合成方法
CN107325101B (zh) * 2017-06-29 2019-03-26 上海合全药物研发有限公司 6-羟甲基-6,7-二氢-5h,9h-咪唑并二氮杂卓-8-羧酸叔丁酯的合成方法
WO2019070910A1 (en) 2017-10-03 2019-04-11 Uwm Research Foundation, Inc. NEW POLYTHERAPY FOR ANXIETY, EPILEPSY AND PAIN DISORDERS
PE20230440A1 (es) 2020-03-31 2023-03-08 Hoffmann La Roche Derivados de benzodiazepinas como pam de gaba a gamma1
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
AR127127A1 (es) * 2021-09-24 2023-12-20 Hoffmann La Roche NUEVOS DERIVADOS DE PIRIDODIAZEPINAS COMO PAM DE GABAA g1
CN118019742A (zh) 2021-09-29 2024-05-10 豪夫迈·罗氏有限公司 作为GABA A γ1 PAM的新颖苯并二氮杂䓬衍生物
CA3232152A1 (en) 2021-10-06 2023-04-13 F. Hoffman-La Roche Ag Benzodiazepine derivatives as positive allosteric modulators of the gaba a gamma1 receptor
WO2023170554A1 (en) 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. Compositions comprising aticaprant
WO2023170550A1 (en) 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. Polymorph forms of aticaprant for use in treating major depressive disorder

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0320992A2 (en) * 1987-12-18 1989-06-21 F. Hoffmann-La Roche Ag Triazolodiazepine derivatives
US4959361A (en) 1987-12-18 1990-09-25 Hoffmann-La Roche Inc. Triazolo(4,3-A)(1,4)benzodiazepines and thieno (3,2-F)(1,2,4)triazolo(4,3-A)(1,4)diazepine compounds which have useful activity as platelet activating factor (PAF) antagonists

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2893992A (en) 1959-07-07 I ii i i
US3886141A (en) * 1971-10-07 1975-05-27 Hoffmann La Roche Preparation of 5-pyridyl benzodiazepine utilizing hexamethylenetetramine
US4440685A (en) * 1974-09-11 1984-04-03 Hoffmann-La Roche Inc. Imidazodiazepines and processes therefor
US4280957A (en) 1974-09-11 1981-07-28 Hoffmann-La Roche Inc. Imidazodiazepines and processes therefor
US4401597A (en) 1978-05-15 1983-08-30 Hoffmann-La Roche Inc. Imidazodiazepines and processes therefor
DE3435973A1 (de) * 1984-10-01 1986-04-10 Boehringer Ingelheim KG, 6507 Ingelheim Diazepine enthaltende pharmazeutische zusammensetzungen mit paf-antagonistischer wirkung
EP0230942B1 (de) * 1986-01-21 1992-04-29 Boehringer Ingelheim Kg Thieno-1,4-diazepine
US5968176A (en) * 1997-05-29 1999-10-19 3Com Corporation Multilayer firewall system
SK13682003A3 (sk) 2001-04-12 2004-07-07 F. Hoffmann-La Roche Ag Dihydrobenzo[b][1,4]diazepin-2-ónové deriváty ako mGluR2 antagonisty II
US7161904B2 (en) * 2002-06-04 2007-01-09 Fortinet, Inc. System and method for hierarchical metering in a virtual router based network switch
US7415723B2 (en) * 2002-06-11 2008-08-19 Pandya Ashish A Distributed network security system and a hardware processor therefor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0320992A2 (en) * 1987-12-18 1989-06-21 F. Hoffmann-La Roche Ag Triazolodiazepine derivatives
US4959361A (en) 1987-12-18 1990-09-25 Hoffmann-La Roche Inc. Triazolo(4,3-A)(1,4)benzodiazepines and thieno (3,2-F)(1,2,4)triazolo(4,3-A)(1,4)diazepine compounds which have useful activity as platelet activating factor (PAF) antagonists

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Drug Design and Discovery, Vol.17, pp.131-171
Journal of Medicinal Chemistry, pp.1928-1934(1996)

Also Published As

Publication number Publication date
EP1490344B1 (en) 2008-03-19
MXPA04009332A (es) 2005-12-12
KR20040098029A (ko) 2004-11-18
EP1490344A2 (en) 2004-12-29
ATE389640T1 (de) 2008-04-15
US20070054881A1 (en) 2007-03-08
ES2300576T3 (es) 2008-06-16
US20070049580A1 (en) 2007-03-01
WO2003082832A3 (en) 2004-04-08
US7119196B2 (en) 2006-10-10
US20100130481A1 (en) 2010-05-27
WO2003082832A2 (en) 2003-10-09
CA2480869A1 (en) 2003-10-09
US20040082573A1 (en) 2004-04-29
DK1490344T3 (da) 2008-06-16
NZ535517A (en) 2007-02-23
JP2005525392A (ja) 2005-08-25
AU2003230754A1 (en) 2003-10-13
US20070299058A1 (en) 2007-12-27
IL163958A0 (en) 2005-12-18
US7235656B2 (en) 2007-06-26
KR20080060286A (ko) 2008-07-01
CN1642924A (zh) 2005-07-20
US20080108605A1 (en) 2008-05-08
AU2003230754B2 (en) 2007-10-25
DE60319812D1 (de) 2008-04-30
DE60319812T2 (de) 2009-04-23
BR0308918A (pt) 2005-01-04

Similar Documents

Publication Publication Date Title
KR100865410B1 (ko) 진정 및 운동실조 효과가 감소된 항불안제
US8835424B2 (en) Selective agents for pain suppression
US20100261711A1 (en) Selective anticonvulsant agents and their uses
US20100004226A1 (en) Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects
JPWO1993007129A1 (ja) 骨粗鬆症治療薬およびジアゼピン化合物
JPH10500998A (ja) ヒドロキシメチル−イミダゾジアゼピン類及びそれらのエステル
JP7648645B2 (ja) Gaba aガンマ1 pamとしての新規ベンゾジアゼピン誘導体
JP7754839B2 (ja) Gaba aガンマ1 pamとしてのベンゾジアゼピン誘導体
USRE47475E1 (en) Selective agents for pain suppression
CA2137668C (en) Benzodiazepines and compositions for treating anxiety and panic disorders, and idiopathic and psychomotor epilepsy
WO2023039018A1 (en) Imidazobenzodiazepines for treatment of cognitive and mood symptoms
DK162495B (da) Analogifremgangsmaade til fremstilling af terapeutisk aktive imidazooe1,5-aaaoe1,4aadiazepin-forbindelser eller farmaceutisk acceptable salte deraf
EP1925614A1 (en) Anxiolytic agents with reduced sedative and ataxic effects
US4016165A (en) Triazino benzodiazepines
NZ547480A (en) Anxiolytic agents with reduced sedative and ataxic effects
Plavsic et al. Studies on Design of Safe Antianxiety Agents Devoid of Adverse Effects
HU202531B (en) Process for producing imidazodiazepine derivatives and pharmaceutical compositions comprising such compounds
AU2007221890A1 (en) Anxiolytic agents with reduced sedative and ataxic effects
HK40104205A (zh) 作为GABA A γ1受体的正向变构调节剂的环庚二烯幷-噻吩幷-二氮杂䓬衍生物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

A107 Divisional application of patent
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20110923

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20121021

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20121021

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000